PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT01964716
- Locations
- ๐ฌ๐ฒ
Fajikunda Major Health Centre, Ksmd, The Gambia, Gambia
๐ฌ๐ฒMedical Research Council Unit, The Gambia, Fajara, The Gambia, West Africa, Gambia
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 243
- Registration Number
- NCT01962207
- Locations
- ๐ซ๐ฎ
South Helsinki Vaccine Research Clinic, Helsinki, Finland
๐ซ๐ฎTampereen yliopisto/ Oulun rokotetutkimusklinikka, Oulu, Finland
๐ซ๐ฎTampereen yliopisto/ Porin rokotetutkimusklinikka, Pori, Finland
Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO
- Conditions
- Hemophilia A
- Interventions
- Device: Refacto FusENGO
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT01959919
- Locations
- ๐ฎ๐น
Anna Chiara Giuffrida, Verona, Italy
๐ฎ๐นOspedale SS. Annunziata - USL 1, Sassari, Sardegna, Italy
๐ฎ๐นAzienda Ospedale Policlinico Consorziale, Bari, Italy
A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers
- Conditions
- Healthy
- Interventions
- Drug: 3 mg PF-06412562Drug: 10 mg PF-06412562Drug: PF-06412562 TBD mgDrug: 25 mg PF-06412562
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT01959594
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01953731
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New Haven, Connecticut, United States
A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
- Conditions
- Healthy
- Interventions
- Drug: PF-06372865 or Placebo or LorazepamDrug: PF-06372865 or Placebo
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT01951144
- Locations
- ๐ณ๐ฑ
Pfizer Investigational Site, Leiden, CL, Netherlands
A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients
- Conditions
- Growth Hormone Deficiency
- Interventions
- Other: Non Interventional Study
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 377
- Registration Number
- NCT01947894
- Locations
- ๐ธ๐ช
Vastra Gotalands Regionen, Skovde, Skaraborg, Sweden
๐ธ๐ชLandstinget i Stockholms Lan, Stockholm, Sweden
๐ธ๐ชSahlgrenska University hospital, Goteborg, Sweden
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
- Conditions
- BRCA 1 Gene MutationBRCA 2 Gene MutationBreast Neoplasms
- Interventions
- Drug: Physician's-Choice
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 431
- Registration Number
- NCT01945775
- Locations
- ๐บ๐ธ
University of California Los Angeles, Los Angeles, California, United States
๐บ๐ธLos Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
๐บ๐ธUniversity of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
- Conditions
- ROS1 Proto OncogeneCrizotinibNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT01945021
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
๐จ๐ณTaipei Veterans General Hospital, Taipei, Taiwan
๐จ๐ณNational Cheng Kung University Hospital, Tainan, Taiwan
5% Topical Ibuprofen (IBU) for Ankle Sprain
- Conditions
- Ankle Injuries
- Interventions
- Drug: Topical IBU twice dailyDrug: Placebo twice dailyDrug: Topical IBU three times dailyDrug: Placebo three times daily
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 304
- Registration Number
- NCT01945034
- Locations
- ๐บ๐ธ
Sunrise Research Institute, Inc., Miami, Florida, United States
๐บ๐ธVisions Clinical Research - Tucson, Tucson, Arizona, United States
๐บ๐ธeStudy Site, San Diego, California, United States